Events
-
-
-
ASCO 2026: Teclistamab extends survival, deepens remissions in relapsed multiple myeloma
-
ASCO 2026: Lancet Commission predict shortfall of 100 million cancer care workers by 2050
-
ASCO 2026: Phase 3 PEAK study could usher in new second-line therapy for GIST
-
ASCO 2026: Personalised vaccine boosts immune activity against brain cancer
-
ASCO 2026: GLP-1s may reduce metastatic progression of certain obesity-related cancers
-
ASCO 2026: Yoga may help cancer survivors sleep better and reduce anxiety, fatigue
-
-
Newfound mechanism may explain why some cancer treatments boost risk of heart disease
A cancer therapy that prompts the body’s immune defenses against viruses and bacteria to attack…
Five new papers highlight cancer inequities, challenges and opportunities in South Asia
A series of five papers, published today in The Lancet Oncology by a University of Pittsburgh-led international…
Peer support may lower depression, stress among cancer patients in low-resource settings
Having cancer can be one of the most physically and emotionally draining experiences of a…
The promise of RAD51 testing in tailoring treatment strategies in early breast cancer
- Trastuzumab emtansine improves long-term survival in HER2 breast cancer
- Study identifies potential new target to overcome breast cancer resistance
- SABCS 2024: PATINA clinical trial may represent a new standard of care for patients diagnosed with hormone receptor positive, HER-2 positive metastatic breast cancer
Tackling racial disparities in prostate cancer
Prostate cancer is the second deadliest cancer in men in the United States. The incidence of prostate cancer in Black…
JOIN THE ONCOLOGY NETWORK
If you would like even more free news articles, access to our exclusive HCP only content including the latest podcasts from The Oncology Podcast and our Industry Partner Podcasts (including links to all papers and show notes), along with all our other resources, head over to The Oncology Network and sign up - FREE forever for HCPs only.